📈 1. China Medical Aesthetics Market Status

iResearch Estimate In 2019, China's medical aesthetics market reached RMB 176.9 billion, with growth slowing to 22.2%.

The revenue ratio of surgical to non-surgical procedures was 6.2:3.8 in 2019 and is projected to shift to 5.2:4.8 by 2023.

Non‑surgical medical aesthetics is expected to grow faster than surgical segments due to technological advancements.

Industry transformation is concentrated in downstream channels. Since 2013, vertical platforms (e.g., So-Young) introduced diversified online customer acquisition.

The value chain consists of upstream suppliers (pharmaceuticals/devices), midstream providers (hospitals/clinics) and downstream channels.

Younger consumers bring more complex consumption patterns.

👩‍⚕️ 2. Medical Aesthetics Consumer Analysis

User profile: predominantly females aged 25-35, bachelor's degree or above, living in first‑ and second‑tier cities. Monthly household income between RMB 20K-50K.

About 10% of current users are male (expert survey).

📌 Decision cycle: surgical users average 44.5 days, non‑surgical 39.3 days. Top decision drivers: sufficient understanding of the procedure (55.3%) and finding a suitable provider/doctor (45.6%).

Consumers’ most sought‑after information: safety (68.4%) and efficacy.

🏥 Provider selection: Reputation and credentials are key for 67.7% of users. When choosing a doctor, peer reputation (65.9%) and professional qualifications (64.7%) dominate.

Overall satisfaction score for preferred institutions: 4.30/5. Procedure outcomes and value for money are the strongest satisfaction drivers.

⚠️ 3. Medical Aesthetics Chaos Analysis

Critical data Only 12% of all medical aesthetic providers are fully compliant with legal requirements.

In 2019, about 13,000 licensed medical cosmetic institutions existed, yet more than 15% of them operated beyond approved scope (e.g., clinics without plastic surgery departments performing blepharoplasty).

More than 80,000 unlicensed beauty salons, nail salons and barber shops illegally performed medical aesthetic procedures nationwide.

Drastic physician shortage: Only 38,343 licensed practitioners actually working in aesthetics in 2019. According to CSAPA (Chinese Society of Aesthetic Plastic Surgery), illegal practitioners exceed 100,000 — licensed doctors represent only 28% of the active workforce.

Additionally, almost 5,000 “itinerant doctors” without formal credentials work inside legal institutions.

🏛️ 4. Institutional Scope Violations & Physician Credentials

Graded management loopholes: Aesthetic procedures are classified into four levels (Level I: blepharoplasty, rhinoplasty; Level IV: malar reduction, mandibulectomy). Many clinics illegally perform Level II+ procedures, while outpatient clinics conduct Level III/IV operations without authorization.

More than 2,000 licensed institutions operate beyond their approved scope.

📌 Physician shortage crisis: Standard training for licensed aesthetic physicians takes 5-8 years, while the black market produces “doctors” through crash courses. Anesthesia-related mortality: 1/100,000 in public aesthetic hospitals vs. 1/1,000 in private illegitimate practices.

💉 5. Injectables & Devices: Shocking Authenticity Rate

iResearch expert survey Only 33.3% of aesthetic injectables in circulation are genuine (NMPA‑approved). For every genuine vial, at least two illegal (counterfeit/grey market) vials are injected.

Illegal injectables lack cold‑chain integrity, leading to infection, necrosis, or disfigurement. The “Amazingel” tragedy persists: some black clinics still disguised it as hyaluronic acid or collagen.

📀 Energy‑based devices: The legitimate device market is 80% dominated by four foreign manufacturers. In illegal beauty premises, over 90% of devices are counterfeit; only<10% are genuine or grey‑market devices (through illegal leasing/smuggling).

⚡ 6. Accident Burden, Complaints & Revision Surgery

⚠️ Black market harms: Approximately 100,000 people are disabled or killed every year due to illegal aesthetic providers. The serious complication rate in legal institutions is below 0.1% (1/1,000), but black‑market users (10–12 million) face a complication rate of about 1%.

📢 Complaints rarely succeed: 8.6% of users intended to complain, only 1.8% filed complaints, and a mere 0.7% obtained successful resolution. Top complained entities: beauty salons, mobile services in hotels, nail/hair salons (all unlicensed).

Revision market size: Approximately 10‑15% of overall market (RMB 17‑25 billion). Revision procedures cost 2‑3x more than primary surgeries, over 90% requiring surgical correction (e.g., trend‑driven reoperation, expired implants, failed previous surgeries).

Users purchased on average 3.14 facial plastic procedures; 13.9% bought more than 6 items (potential over‑aesthetic tendency).

🧠 7. Cognitive Gaps & Light Aesthetic Misperceptions

🔍 Lack of awareness about legality: Many users never verify an institution’s “Medical Institution License” nor the physician’s practice certificate. The knowledge gap is wider among users who intend to complain.

Many consumers cannot differentiate between cosmetology (life beauty services) and medical aesthetics.

💡 Light aesthetic misconception: Only 39.1% of users correctly defined light aesthetics as non‑surgical (lasers, injectables, energy‑based). 60.9% erroneously considered surgical procedures such as liposuction, breast augmentation, facial implants as “light aesthetics”.

This confusion allows illegal businesses to thrive, as beauty salons trick consumers into receiving dangerous medical procedures.

Overseas medical aesthetics risks: Lack of aftercare, information asymmetry, language barriers and aesthetic differences lead to high risk. Patients to South Korea/Japan should be extremely cautious.

🔒 8. Industry Supervision & The Path Forward

Since 2002, China has successively tightened regulations on medical aesthetics. Annual crackdowns on illegal practices began in 2014, and in 2020 eight ministries reinforced enforcement.

Nevertheless, the black market persists. iResearch recommends building a multi‑stakeholder information platform integrating provider licenses, physician qualifications, and full traceability of injectables/devices.

The next 3-5 years will see deep industry consolidation. Enhanced digital supervision and consumer education will pave the way for market recovery. Training programs (CSAPA proposes training 50,000 physicians over 5 years) are essential to fill the talent gap.

※ Sources: iResearch Consulting Group calculations, National Health Commission Yearbook, CSAPA, expert interviews and user survey (N=700), March 2020. For educational and public awareness purposes.